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Abstract 
Caffeine is commonly used to enhance attentional processes. However, 
contention remains regarding the extent to which each attentional mechanism is affected 
by caffeine, and whether caffeine enhances attention over-and-above improvements in 
general arousal and sustained attention. Subsequently, the present study examined the 
acute effects of caffeine on behavioural (reaction time & accuracy) and 
electrophysiological (N1 ERP amplitude) measures of attention. During two separate 
sessions (separated by 7-14 days), twenty (14 female & 6 male) healthy, low consumers 
of caffeine (<150mg/day) completed an Attentional Network Task prior to ingesting 
either caffeine (200mg) or placebo, and again 30-minutes following ingestion. While a 
partial effect of caffeine upon the alerting and executive control networks was found, 
results of the present study suggested improvements in reaction time and accuracy 
following caffeine predominantly reflected a maintenance of general arousal and tonic 
alertness. It was concluded that caffeine primarily enhanced attentional processing by 
preventing fatigue and sustaining attention.  
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Caffeine has been used as a means of cognitive enhancement for centuries, typically 
in the form of coffee and tea (Snel & Lorist, 2011). Today, caffeine is the most 
commonly consumed psychoactive substance, with over 80% of the human population 
estimated to ingest it daily (Heckman et al., 2010). Given the prevalence of caffeine 
consumption, obtaining a comprehensive understanding of its effects on the brain and 
cognition is essential. Caffeine is a naturally occurring alkaloid found in over sixty plant 
species, including coffee and cocoa beans, kola nuts, and tea leaves (Spiller, 1997). 
Caffeine has been added to energy drinks, cola-type soft drinks, pre-work out and 
dietary supplements, as well as prescription and non-prescription medications (Zhang et 
al., 2012). Caffeine is typically used for its temporary, relatively mild, fast-acting 
stimulant effects, namely improved sustained attention, reduced fatigue, and elevated 
mood (McLellen, Caldwell, & Liebermann, 2016; Nehlig, 2010). Attentional processes 
often precede other psychological and behavioural functions (e.g., memory, mood, 
motor-output), and are of central importance throughout the present paper (Becker & 
Leinenger, 2011; Savill, Moree, Dundon, Marcora, & Klein, 2018). Attention operates 
to efficiently reduce information overload by directing cognitive resources to 
necessitous cognitive subsystems (Luck et al., 2000). Attentional performance can be 
measured using behavioural indices such as reaction time (RT) and accuracy (Eriksen & 
Erikson, 1974; Posner, 1980). That caffeine can have a cognitive enhancing role in 
improving behavioural indicators of attention appears close to consensus (Einöther & 
Giesbrecht, 2013; McLellen et al., 2016). However, contention remains regarding the 
attentional mechanisms responsible for the performance advantages observed following 
caffeine consumption, and the extent to which these mechanisms are affected (Brunye, 
Mahoney, Lieberman, & Taylor, 2010a). Electroencephalography (EEG) and Event-
Related Potentials (ERP) can assist with generating specificity regarding the effect of 
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caffeine on attentional performance (Einöther & Giesbrecht, 2013). While many studies 
examining the effect of caffeine upon attentional processes have used functional 
Magnetic Resonance Imaging (fMRI), a gap in the psychopharmacology literature 
persists regarding EEG/ERPs (Koppelstaetter et al., 2010).  
Pharmacology, metabolism and mechanisms of action 
Caffeine (1,3,7-trimethylxanthine) can be absorbed through mouth, throat and 
stomach membranes, with caffeine plasma concentrations peaking as quickly as 30 
minutes post-ingestion, with a half-life of approximately 4-6 hours in healthy adults 
(Adan et al., 2008). Absorption rates can be affected by numerous physiological and 
environmental factors that can result in greater resistance or sensitivity to caffeine 
(Yang et al., 2010). Contributing factors include biological age and sex, genetic 
variability, recent and habitual caffeine use, nicotine and THC use, recent food intake 
and diet, sleep hygiene, pregnancy, sickness and disease (McLellen et al., 2016; Renda 
et al., 2015). Once absorbed, caffeine is distributed throughout the body via the blood 
stream, and readily crosses the blood-brain-barrier, before entering extracellular space 
immediately prior to various neural membrane (Urry & Landolt, 2014). Located in 
varying concentrations within the neural membrane are adenosine receptors, where the 
psychostimulant effects of caffeine appear to begin. 
Adenosine is a central nervous system (CNS) neuromodulator, attenuating the 
activity of vigilance-promoting neurons in the brain stem, basal forebrain, and 
hypothalamus (Urry & Landolt, 2014; Yang et al., 2010). Adenosine-specific receptors 
(predominantly A1 & A2a receptors) can be found throughout the CNS, predominantly 
in the brain stem, hippocampus, cerebral cortex, cerebellum, and hypothalamic nuclei. 
Adenosine is formed within neurons by intrinsic membrane glycoproteins, released into 
extracellular space following periods of relatively high energy demand, and gradually 
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accumulates at adenosine receptors throughout the day, before being cleared during 
sleep (Urry & Landolt, 2014). As an inhibitory neurotransmitter, when adenosine binds 
to its receptors, neural activity decreases, and fatigue sets in. Caffeine on the other hand, 
is an adenosine-receptor antagonist, i.e., it mimics adenosine structurally, but not 
functionally. When caffeine binds to adenosine receptors it blocks the normal neural 
reductions and fatiguing effects of adenosine, subsequently extending wakefulness. 
Neurotransmitters essential for arousal, attentiveness, motricity, motivation, and 
learning, such as norepinephrine, histamine, acetylcholine, dopamine, serotonin, and 
glutamate, are either directly or indirectly uninhibited when caffeine binds to adenosine 
receptors (Oken, Salinsky, & Elsas, 2006; Urry & Landolt, 2014; Yang et al., 2010). 
This process is thought to largely underlie research that has shown improvements in 
attentional performance following caffeine ingestion (McLellen et al., 2016).  
Attention 
Attention refers to the capacity of an individual to operationalise, direct and 
engage concentrated effort onto a stimulus (Carrasco, 2011; Fan et al., 2002; Petersen 
and Posner, 2012). Attention can be selective, divided, spatial, and sustained, and can be 
used to recognise and engage stimuli in different modalities (i.e., visual, auditory, 
tactile). For visual attention, concentrated effort over an object, features, or a spatial 
configuration facilitates the formation of a high-resolution focal area and low-resolution 
visual periphery (Carrasco, 2011). Tasks and stimuli can be prioritised when focused 
upon, enabling information to be processed selectively. A visually selected stimulus or 
task is afforded a degree of clarity corresponding to a combination of relatively rapid, 
reflexive bottom-up influences, largely from limbic and sensory modalities, and slower, 
more deliberate top-down regulation from neocortical sites (Fan et al., 2005; Yanaka, 
Saito, Uchiyama, & Sadato, 2010). Examples of simple, bottom-up processes include 
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arousal, sustained attention, response readiness, and orienting. While complex, top-
down processes include executive functions such as response inhibition (Petersen & 
Posner, 2012).  
Behavioural Measures of Attention 
Tonic alertness. To quantify simple and complex attentional processes reaction 
time (RT) and accuracy scores have been assessed on a variety of basic psychomotor 
tasks (Einöther & Giesbrecht, 2013). Simple reaction time (SRT) tasks involve a single 
stimulus and response; for example, a button push following the presentation of a target 
on a computer screen (Dreary, Liewald, & Nissan, 2011). The time required to respond 
to the presentation of the target stimulus is thought to reflect basic sensory input 
systems (i.e., a stimulus) and output systems (i.e., a response). When performed 
repeatedly over time, basic SRT tasks can provide a measure of general arousal and 
tonic alertness, i.e., non-specific activation of the cerebral cortex in relation to sleep-
wake cycles, and the ability to maintain concentration for prolonged periods of time, 
respectively (Oken, et al., 2006; Ratcliff & Van Dongen, 2011). Throughout the present 
paper tonic alertness has been used synonymously with sustained attention, of which 
considerable conceptual overlap occurs. Underlying tonic alertness is a midbrain-
thalamus-anterior cingulate cortex (ACC) network, extending to bilateral frontal and 
parietal cortices (Fan et al., 2005; Yanaka et al., 2010). Several neurotransmitter 
systems modulate thalamic and cortical activity, including the hippocampal-
acetylcholine (sustained attention), locus coeruleus-norepinephrine (vigilance), raphe-
serotonin (mood), and tuberomammillary-histamine (arousal) systems (Carter et al., 
1995; Oken et al., 2006). 
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Phasic alertness. On a basic SRT task the addition of a centrally located 
warning cue (e.g., an asterisk) presented immediately prior to target onset reliably 
improves RT, indicative of enhanced sensory processing (Fan et al., 2002; Yanaka et 
al., 2010). This ‘warning effect’ appears to reflect preparatory neural activation of the 
midbrain-thalamus-ACC network and pre-supplementary motor area (pre-SMA), the 
same brain regions involved during tests of tonic alertness (Yanaka et al., 2010). This 
‘neural priming’ is typically experienced as an elevated state of anticipation, referred to 
as phasic alertness (Oken et al., 2006). Phasic alertness is thought to enhance sensory 
processing by improving signal-to-noise ratios, subsequently reducing the threshold for 
a response. Tonic and phasic alertness are considered subsystems of an alerting network 
(Petersen & Posner, 2012).  
Orienting. The warning effect becomes more pronounced with the use of spatial 
cues; warning cues that reliably predict the location of an upcoming target stimulus (Fan 
et al., 2002). Orienting refers to the ability of an individual to direct their ‘spotlight’ of 
attention away from one stimulus and onto another, assisting in the selection of specific 
information, and ultimately accelerating response times (Posner, 1980). Orienting can 
occur in a bottom-up, reflexive manner, as when a threatening stimulus comes into view 
and attention rapidly shifts toward it (Fan et al., 2009). Reflexive orienting appears to be 
primarily supported by a cholinergic, ventral frontal-parietal system, which includes the 
temporo-parietal junction and superior colliculus (Petersen & Posner, 2012). Orienting 
can also proceed in a top-down, voluntary manner, as when a decision to acquire an 
object prompts a visual search for said object (Fan et al., 2009). Voluntary orienting of 
attention occurs more slowly, is more vulnerable to inhibition and appears to be 
underpinned by a predominantly cholinergic, dorsal frontal-parietal system (Petersen & 
Posner, 2012). Reflexive and voluntary orienting can be overt, whereby the head and/or 
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eye shifts toward a target stimulus; or covert, in which the attentional processing of a 
target stimulus is enhanced without body or eye movements (Hunt & Kingstone, 2003; 
Posner et al., 1984). Overt and covert orienting appear to be independent structures of 
the inferior and superior parietal lobe, activated according to bottom-up or top-down 
regulation (Hunt & Kingstone, 2003).  
Response inhibition. In a choice reaction time (CRT) task complexity and 
uncertainty are added with the introduction of multiple stimuli and responses, indexed 
by slower RTs and reduced accuracy scores compared with SRT tasks (Dreary et al., 
2011). Examples of CRT tasks include flanker-type tests, whereby a target is presented 
on a computer screen surrounded by flanker stimuli that could facilitate or hinder 
performance (Eriksen & Eriksen, 1974). The target stimulus could vary, along with the 
type of response required. If the flanker stimuli are similar, or congruent, to the target 
stimulus then performance is generally facilitated. Whilst performance is typically 
hindered when flanker stimuli are contradictory, or incongruent, with the target stimulus 
(Fan et al., 2002; Dreary et al., 2011). Scores on flanker tasks can provide a measure of 
top-down executive processes, such as response inhibition, the ability to focus upon a 
target stimulus while blocking distractor stimuli (Petersen & Posner, 2012). Response 
inhibition appears to be underpinned by densely dopaminergic innervation in ACC and 
lateral prefrontal cortices (Fan et al., 2005).  
Electrophysiological Measures of Attention 
Attentional processes can be investigated at a psychophysiological level by 
combining psychomotor tasks with electroencephalography (EEG) and Event-Related 
Potentials (ERP; Luck, Woodman, & Vogal, 2000; Neuhaus et al., 2010). 
Electroencephalography is a recording technique used to monitor patterns of brain 
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activity at the scalp (Luck et al., 2000). An averaged ERP waveform is generated by 
dividing the larger EEG recording into trial-specific segments and averaging all 
segments according to trial type. An ERP contains a series of positive (P) and negative 
(N) amplitudes (measured in millivolts), each of which peak at varying latencies 
(milliseconds), with greater amplitudes indicative of increased cortical activity. An ERP 
component is referred to with a letter, indicating polarity (Positive or Negative), and a 
number, indicating peak latency (milliseconds). The visual N100, or N1, ERP 
component has been shown to correlate with sustained attention and orienting (Luck et 
al., 2000; Vogal & Luck, 2003; Neuhaus et al., 2010).  
Vogel and Luck (2003) demonstrated larger posterior N1 amplitudes on various 
CRT tasks compared to SRT tasks. This suggested increased cortical activation with 
greater task complexity. However, this study did not utilise central or spatial warning 
cues. Neuhaus et al. (2010) used an Attentional Network Task (ANT), which combines 
a cued detection test (Posner, 1990) with the Eriksen flanker paradigm (Eriksen & 
Eriksen, 1974), to measure tonic alertness (no warning cue), phasic alertness (central 
warning cue), orienting (spatial warning cue), and response inhibition (flankers). 
Averaged ERP N1 modulation was explored across 32 electrode channels, and 
differences between attentional systems were determined using ERP waveform and 
topographical analysis. Cue effects on the N1 ERP component were clearly evidenced; 
spatial cues elicited a significantly greater amplitude than central cues, which elicited a 
significantly greater amplitude than no cue trials. This was particularly evident at 
posterior-parietal channels for alerting cues, and posterior-occipital channels for 
orienting. These findings align with conceptions of attention-related N1 being generated 
at the extrastriate cortex (Fu, Greenwood, & Parasuraman, 2005; Padilla et al., 2006).  
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Caffeine on Attention 
Alerting. Performance improvements have been consistently demonstrated 
across various basic psychomotor tasks with a broad range of caffeine doses (37-
600mg), strongly suggesting an effect of caffeine on arousal and tonic alertness 
(Christopher et al., 2005; Einöther & Giesbrecht, 2013; Haskell, Kennedy, Milne, 
Wesnes, & Scholey, 2008). While RTs showed significant improvement on SRT tasks 
across several studies, scores were rarely assessed in terms of accuracy (Childs & de 
Witt, 2006; Fine et al., 1994; Martin & Garfield, 2006). Using a SRT task to assess 
tonic alertness, Kelemen and Creeley (2001) found caffeine reliably improved both RT 
and accuracy. On tasks that included warning cue trials, caffeine has been shown to 
significantly reduce RT, suggesting an enhancement in phasic alertness (Brunye et al., 
2010a, 2010b), but not always (Giles et al., 2012; Giles et al., 2016). 
Foxe et al. (2012) combined a SRT task with EEG to monitor the effect of 
caffeine on EEG waveforms. Alpha-band oscillatory activity was significantly reduced 
following a caffeine dose as low as 50mg (for caffeine content of commonly used 
products see Table 1). Alpha-band oscillations generally index fatigue and reduced 
cortical activity (Pfurtscheller, 1992). Subsequently, caffeine seemingly reduced the 
decline in cortical activity in fatigue-inducing tasks. This parallels with conceptions of 
caffeine as an adenosine modulator within the CNS, blocking adenosine, and sustaining 
neural activity (Urry & Landolt, 2014). 
Orienting. Smith, Brockman, Flynn, Maben, & Thomas (1993) found early 
evidence for an improvement in orienting following caffeine. Smith et al. compared 
twenty-four habitual, moderate (~240mg/day) caffeine consumers on a variety of basic 
SRT and CRT tasks following either caffeine (1.5 or 3mg/kg dose) or placebo. RTs 
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improved with caffeine on tasks relevant to orienting. However, the tasks predominantly 
measured alerting, and large variability in caffeine consumption without a pre-test 
abstinence period made any caffeine-related conclusions problematic. More recently, 
caffeine has not been shown to generate orienting effects (Brunye et al., 2010a; Brunye 
et al., 2010b; Giles et al., 2012; Giles et al., 2016). Brunye et al. (2010a, 2010b) 
included a 12-hour abstinence period and used an ANT to compare the effect of several 
caffeine doses (0mg, 100mg, 200mg, 400mg) on alerting, orienting and response 
inhibition for habitual, low consumers of caffeine (M=42.5mg/day) and habitual, high 
consumers (M=592.3mg/day). Although, caffeine did not enhance orienting 
performance across either study, and a decrement in orienting performance was seen for 
low caffeine consumers at 400mg. The finding of no differential effect of caffeine upon 
the orienting network was thought to reflect work that suggests caffeine acts primarily, 
directly or indirectly, upon densely dopaminergic and norepinergic regions of the 
striatum, ACC, and frontal cortices, not involved in orienting (Brunye et al., 2010a; Ko 
et al., 2009; Volkow et al., 2015).  
With regards to electrophysiological research, Ruijter, Lorist, Snel and De Ruiter 
(2000) assessed twelve participants on a ten-minute complex sustained attention task 
following both caffeine and placebo. A combination of ERP and behavioural indices did 
not reveal any effect of caffeine on orienting. However, it was suggested the task was 
probably too demanding to find an effect. The researchers also focused on positively 
evoked potentials, such as P2 and P3 components. However, studies that have 
investigated the effect of caffeine on orienting are sparse and limited, particularly those 
utilising ERP indices, preventing any firm conclusions to be drawn for the effect of 
caffeine on orienting.  
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Table 1 
Caffeine Content of Commonly Used Products 
  Caffeine (mg) 
Per 125ml cup   
 Filtered, percolated coffee 60-100 
 Instant coffee 35-50 
 Cappuccino 60 
 Decaf 2-4 
 Espresso (per 50ml) 50-60 
 Tea 20-45 
Per 100ml   
 Iced tea 3-12 
 Cola soft drink 3-11 
 Energy drinks 30 
 Chocolate drinks 2-4 
Per 50g   
 Milk Chocolate 2-25 
 Dark Chocolate 8-60 
 Chocolate ice cream 2-10 
 Prescription and non-prescription medication 25-100 
Source: Snel and Lorist (2003).  
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Executive control. Most studies investigating the effect of caffeine on response 
inhibition have found significant effects of caffeine on performance (Einöther & 
Giesbrecht, 2013; McLellen et al., 2016). On a CRT task requiring participants to select 
a central target letter flanked by peripheral distractors, caffeine consistently decreased 
response times (Christopher et al., 2005; Hewlett & Smith, 2006; Smith et al., 2003) and 
occasionally improved accuracy (Smith et al., 2005). Utilising Eriksen flanker and 
Eriksen-adapted flanker tasks, RTs have been shown to improve following caffeine 
(150-250mg) compared with placebo (Addicott & Laurienti, 2009; Eriksen & Eriksen, 
1974; Kenemans, Wieleman, Zeegers, & Verbaten, 1999; Tieges, et al., 2009). More 
recent research using ANTs showed response inhibition was enhanced by caffeine for 
low (Brunye et al., 2010a) and moderate-high caffeine consumers (Brunye et al., 2010b; 
Giles et al., 2012; Giles et al., 2016). These effects were thought to reflect caffeine-
induced innervation of densely dopaminergic regions of the ACC and prefrontal cortex 
(Brunye et al., 2010a; Volkow et al., 2015).  
Other studies have failed to show sensitivity of response inhibition to caffeine 
(Rujiter et al., 2000; Tieges, Snel, Kok, & Ridderinkhof, 2009). Tieges et al. (2009) 
assessed the effect of a 3mg/kg body weight dose of caffeine on response inhibition. A 
flanker task was administered to healthy participants in a double-blind, placebo-
controlled, within-subjects experiment, and differences in overall performance on the 
flanker task between caffeine and placebo conditions were negligible. These results 
were thought to reflect either too small a dose and/or insufficient reversal of adverse 
withdrawal symptoms (James, 2014). However, this cannot be determined because no 
baseline data was acquired (Tieges et al., 2009).  
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Methodological Limitations 
Previous studies that measured the behavioural effects of caffeine according to dose 
have found speed-accuracy advantages as low as 50mg on tests of alertness (Foxe et al., 
2012; Wilhelmus et al., 2017). For low caffeine consumers (<150mg/day), alerting and 
executive control effects tended to reach optimal performance at a moderate dose 
(~200mg), before asymptoting at higher doses (Brunye et al., 2010a). For habitual, 
moderate-high consumers (>150mg/day), alerting and executive control effects 
optimised with a high dose (~350-450mg), and became asymptotic thereafter (Brunye et 
al., 2010a; Brunye et al., 2010b; Tieges et al., 2004). Recent studies have shown that 
following longer periods of abstinence, habitual consumers required less caffeine to 
elicit an effect on performance (Giles et al., 2012). This ‘rise and tapering-off’ in 
performance has been interpreted in terms of the classic inverted U-curve of 
arousal/performance, whereby increasing arousal facilitates improvements in 
performance, before plateauing and eventually hindering performance (Nehlig, 2010). 
While confounds such as task difficulty, caffeine sensitivity, body-weight, and 
personality make the inverted U-curve a somewhat simplistic explanation, the dose-
related effect of caffeine appears similarly curvilinear, with an optimal dosage central to 
the arousal/performance curve (Anderson, 1994; Diamond, 2005; Renda et al., 2015).  
The Present Paper 
The aim of the present study was to further investigate the effects of caffeine 
(200mg) on behavioural measures (RT & accuracy) of alerting, orienting and executive 
control, and electrophysiological measures (N1 ERP component) of alerting and 
orienting with healthy, low caffeine consumers. An Attentional Network Task (ANT) 
was used to differentiate between three attentional networks as described by the 
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Attention Network Theory (Fan et al., 2002; Petersen & Posner, 2012). The ANT is a 
computer-based activity which combines a cued detection paradigm (Posner, 1980) with 
a flanker task (Eriksen & Eriksen, 1974). Behavioural measures (RT & accuracy) are 
used to index performance on the ANT. Evidence from behavioural and neural research 
provide support for the efficacy of the attentional network theory and ANT for 
differentiating attentional mechanisms (Fan et al., 2002; Neuhaus et al., 2010; Petersen 
& Posner, 2012). The present study also indexed neural correlates of attention (tonic, 
phasic, & orienting) via an occipital N1 ERP component. 
The attentional network theory posits that underlying attention are three 
functionally and anatomically distinct networks; the alerting, orienting and executive 
control networks (Peterson & Posner, 2012). The alerting network can be discussed in 
terms of tonic and phasic alertness; where tonic alertness refers to the intrinsic state of 
arousal or wakefulness of an individual, and phasic alertness refers to the ability of an 
individual to manipulate the level of response readiness to a stimulus or task. The ANT 
assesses tonic and phasic alerting with a two-CRT task containing trials with either no 
warning cue (tonic) or a location-naïve warning cue (phasic). The difference between no 
cue and central cue conditions reflects an overall score for the alerting network (Fan et 
al., 2002). Orienting refers to the ability to redirect the ‘spotlight of attention’ from one 
stimulus onto another. Orienting is measured by the ANT using a two-CRT task with a 
spatial warning cue that validly predicts the location of an upcoming target stimulus. 
The difference between central cue and spatial cue conditions reflects the orienting 
network. In the context of the ANT the executive control network refers to response 
inhibition, the ability to block out distracting stimuli to prioritise a target stimulus. 
Executive control is measured by comparing trials containing congruent flankers with 
trials containing incongruent flankers. Differentiating between attentional networks 
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affords the capacity to discern whether caffeine influences specific attentional 
mechanisms over-and-above general arousal and tonic alertness.  
A double-blind, within-subjects design, with two levels of a caffeine condition 
(0mg, 200mg) was conducted. The influence of caffeine on the attentional networks 
(alerting, orienting, & executive control) was assessed by combining the ANT with 
EEG, specifically measuring RT (ms), accuracy (% correct responses), and the N1 ERP 
waveform at the midline occipital electrode site (Oz). It was expected that on the ANT, 
participants would exhibit significantly reduced overall RTs following caffeine 
compared with placebo. More specifically, it was predicted that RTs would be slowest 
for no cue, significantly faster for central cues (alerting), and fastest for spatial cues 
(orienting); and that with caffeine RTs would be significantly faster for all cues in 
comparison to placebo equivalents. Congruent trials were expected to produce 
significantly faster RTs than incongruent trials, and caffeine was expected to produce 
significantly faster RTs at congruent and incongruent trials. Greater attentional network 
effects were expected for alerting and executive control following caffeine, but not 
orienting. Accuracy scores following caffeine were expected to be significantly higher 
than placebo. It was predicted that the N1 amplitude would be smallest for no cue, 
greater for central cue (alerting), and greatest for spatial cue (orienting); and with 
caffeine, N1 amplitude would be greater for all cues relative to placebo equivalents.  
Method 
Participants  
Twenty-three healthy, low caffeine consuming (M= 45.69mg/day, SD=38.47) 
participants (6 male, 14 female), aged 19-29 (M=22.10, SD=2.99) were recruited for the 
present study. An a priori G*Power estimate indicated a sample of 24 participants was 
sufficient to detect moderate sized effects (f=.25, α=.05, power=.90). Three participants 
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were excluded due to low accuracy (<75%; n=2) and withdrawn consent (n=1) for a 
total of 20 participants. While 127 participants completed the screening questionnaire, 
the aim was to reduce the potential impact of withdrawal and tolerance effects, so only 
those with no-to-low caffeine consumption (0-150mg/day) were recruited (M=45.69, 
SD=38.47). Participants were either psychology undergraduates at the University of 
Tasmania (UTAS), and received course credit, or paid volunteers recruited via 
advertisements throughout the UTAS campus, social media, or peer referral, and 
received a $40 gift voucher for their time and expenses.  
The screening questionnaire contained the following exclusion criteria: habitual 
tobacco use; a history of illicit drug use (any consumption in past month or ≥8 lifetime 
uses);  prescribed medication use; alcohol dependence or abuse as indicated by scores 
on the Alcohol Use and Disorders Identification Test (AUDIT; Saunders, Aasland, 
Babor, De la Fuente, & Grant, 1993; exclusion with scores ≥16); high levels of 
psychological distress as indicated by scores on the Kessler Psychological Scale (K10; 
Kessler et al, 2002; exclusion with scores ≥30), current or notable history of mental 
health conditions, contraindications to caffeine such as hypertension or anxiety, and 
pregnancy. English as first language, normal-corrected vision and hearing, and a body 
mass index (BMI) higher than 18.5 (not underweight) was also required to participate.  
If eligible beyond the screening process, two experimental sessions 
(approximately 2.5 hours each, 7-14 days apart) at the UTAS Cognitive Neuroscience 
Laboratory were organized via an anonymous phone call and email correspondence. 
Participants were asked to refrain from using illicit drugs prior to and during testing, 
and to abstain from any alcohol use 24 hours prior to testing. To ensure consistency in 
caffeine consumption, participants were asked to abstain from caffeine at least four 
hours before arrival. Participants were also asked to limit food intake to a light meal on 
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the day of testing. Each experimental session began at approximately 1pm to control for 
potential time-of-day effects (Revelle, Humphreys, Simon, & Gilliland, 1980). The 
present study was approved by the University of Tasmania Human Ethics Committee 
(see Appendix A). 
Materials and Apparatus 
An online screening questionnaire was comprised of items relating to: 
demographic information; handedness; caffeine intake (type, frequency & quantity); 
tobacco and nicotine use; alcohol habits; past and present physical, neurological and 
psychological conditions (e.g., skin sensitivity, epilepsy, anxiety & depressive 
disorders); medication; BMI; language.  
The Alcohol Use and Disorders Identification Test (AUDIT; Saunders et al., 
1993) was used as part of the screening questionnaire to assess hazardous alcohol use, 
alcohol dependence, and problematic patterns of alcohol-related behaviour (Bohn, 
Babor, & Kranzler, 1995). The AUDIT contains ten questionnaire items, with seven 
items relating to frequency rated on a 5-point scale (e.g., ‘never’ to ‘daily or almost 
daily’), two items relating to harmful use rated on a 3-point scale (e.g., ‘no’ to ‘yes, 
during the last year’), and one item relating to quantity rated on a 5-point scale (e.g., ‘1 
or 2’ to ’10 or more’). An overall score ≥16 is indicative of problematic use (Saunders 
et al., 1993). Psychometric properties of the AUDIT, including test-retest reliability and 
internal consistency, are robust (Bohn et al., 1995; Reinert & Allen, 2007).  
The Kessler Psychological Distress Scale (K10; Kessler et al., 2002) was used as 
part of the screening questionnaire to assess recent psychological wellbeing. The K10 
contains ten questionnaire items relating to psychological distress (e.g., ‘about how 
often did you feel depressed?’), rated on a 5-point Likert scale (e.g., from ‘1= all of the 
time’ to ‘5= none of the time’). Scores ≥30 indicate a very high level of psychological 
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distress (Myer, Stein, Grimsrud, Seedat, & Williams, 2007). The K10 is increasingly 
utilised in neuropsychological research, evidenced to have high internal consistency 
(Cronbach’s α=.93), and been validated across various settings (Andrews & Slade, 
2001; Kessler et al., 2002; Myer et al., 2007).  
An experimental session questionnaire (See Appendix B) was used during each 
session to record and control for potentially confounding variables. The checklist 
contained questions relating to: alcohol and illicit drug use; prescribed and non-
prescribed medications; caffeine intake (quantity and recency of use); tobacco and 
nicotine use; food consumption (types and recency of use); height and weight (BMI); 
and sleep (quantity).   
The Wechsler Test of Adult Reading (WTAR; Wechsler, 2001) assessed verbal 
intelligence by asking participants to read aloud a list of 50 irregularly spelled words 
(e.g., ‘lugubrious’). A standardised score can be generated by combining the raw score 
(number of correct responses) with the participants age. Standardised scores on the 
WTAR have been shown to correlate strongly with overall verbal IQ (r=.75) and full-
scale IQ (r=.73; Wechsler, 2001). The WTAR was developed in relation to the 
Wechsler Adult Intelligence Scale-Third Edition (WAIS-III; Wechsler, 1997), and high 
internal consistency (Cronbach’s α =0.87-0.97) and test-retest reliability (r=.90-.94) 
have been demonstrated (Wechsler, 2001).  
A Profile of Mood States-Short Form (POMS-SF; Shacham, 1983) provided a 
subjective account of mood at pre- and post-ingestion. The POMS-SF consisted of 37 
survey items (e.g., ‘energetic’) that participants rated on a 5-point scale (e.g., from 0= 
not at all’, to ‘4= extremely’). The POMS-SF is comprised of nine subscales, including: 
Tension-Anxiety; Depression-Dejection; Anger-Hostility; Vigour-Activity; Fatigue-
Inertia, and; Confusion-Bewilderment. Internal consistency estimates for the POMS-SF 
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scales appear equivalent and superior to those of the original POMS (Curran et al., 
1995; Shacham, 1983). 
The Karolinska Sleepiness Scale (KSS; Åkerstedt & Gillberg, 1990) assessed 
subjective levels of wakefulness at pre- and post-ingestion. The KSS asks participants to 
circle one of the nine statements that most accurately reflected how they felt, from 1 
(‘extremely alert’) through 5 (‘neither alert nor sleepy’) to 9 (‘very sleepy, great effort 
to keep awake, fighting sleep’), with lower scores indicating a greater level of 
wakefulness.  
Visual-Analogue Scales (VAS) provided a measure of subjective performance 
and drug effects (See Appendix C). The VAS of Subjective Performance consisted of 
four statements regarding alertness (e.g., ‘I feel alert’), and were used at pre- and post-
ingestion. While the VAS of Subjective Drug Effects consisted of four concentration- 
and drug-related items (e.g., ‘Liking of drug effect’), and were used at post-ingestion. 
Participants rated themselves for each item by marking along a 10cm black line (e.g., 
from ‘strongly agree’ to ‘strongly disagree’), thereby scoring between zero and ten, with 
lower scores indicating greater agreement for VAS-performance items and less effect 
regarding VAS-drug items. A manipulation check was included in the VAS of Drug 
Effects questionnaire form, asking participants to indicate their level of confidence in 
having ingested caffeine (0-100%).  
Attentional Network Task 
Adapted from Neuhaus et al. (2010), an Attentional Network Task (ANT) was 
utilised (see Figure 1). The ANT was performed on a computer with NeuroSCAN Stim2 
software. For each trial, a white fixation cross (0.2cm) on a black computer screen was 
presented for 400 milliseconds (ms), followed by a 100ms pseudo-randomised 
generation of one of three cue stimuli: central cue, spatial cue, or no cue. The central 
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cue involved the presentation of a white asterisk (0.4cm) overlaying the central fixation 
cross. The spatial cue also involved the appearance of an asterisk (0.4cm), but 1.01 
degrees above or below the central fixation point, always validly predicting the location 
of an upcoming target stimulus.  
 
 
 
Figure 1. The Attentional Network Task (adapted from Neuhaus et al., 2010). 
 
A 400ms inter-stimulus interval (ISI) separated the cessation of the central and 
spatial cues and the presentation of the target stimulus. For no cue trials an asterisk did 
not appear on screen, and instead the central fixation cross remained on screen until the 
presentation of a target stimulus. The target stimulus was the central arrow within a 
3.4cm row of five horizontally-directed arrows (pointed either left or right). The row of 
arrows remained on screen for 1000ms or until a left-or-right response was selected. 
Responses were made via a left-or-right button push on a Cedrus Response Pad (Model 
RB-740). A left-pointed target arrow indicated a left button push using a left-hand index 
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finger, and vice-versa for a right-pointed target arrow. The two arrows on each side of 
the target arrow (flankers) were either congruent (pointed in the same direction as the 
central arrow) or incongruent (pointed in opposite direction as central arrow). Inter-trial 
intervals of 1000ms, 1100ms, 1200ms, or 1300ms were randomly allocated to each 
sequence of trials. The task consisted of 10 practice trials followed by 480 test trials 
(with an opportunity for a break every 120 trials).  
Electrophysiological (EEG) recording 
Cortical activity was recorded using a 32-channel Quik-Cap, connected to a 
computer-based NeuroSCAN system (Scan 4.5 software). Electrode impedance was 
kept at less than 10kΩ, with electrical activity of the scalp continuously recorded at 
1000Hz via 32 electrode sites, in accordance with the international 10-20 electrode 
placement system (Nuwer et al., 1998). All channels were referenced to an electrode at 
each mastoid, and horizontal and vertical electro-oculographic activity were recorded 
from the outer canthi of each eye and above and below the left eye, respectively.  
Continuous EEG and behavioural data were merged and filtered through a Zero-
phase-shift low-pass filter (30Hz, 24Db/Oct) during the editing process. Ocular artefact 
rejection was utilised to reduce potential signal contamination due to eye blinks, eye 
rotation and head movements. Epochs of 1000ms, beginning 100ms prior to stimulus 
presentation and finishing 900ms post-stimulus, were extracted from the dataset. 
Baseline correction and artefact rejection were performed on each epoch, with artefacts 
excluded above 70µV or below -70µV. The N1 amplitude at the midline electrode (Oz) 
was then determined via a grand averaging of EEG waveforms across all participants 
for each condition. An automated peak-selection procedure determined the occipital N1, 
pin-pointing the maximum amplitude from 80-140ms post-stimulus onset, followed by 
visual inspection and manual correction.  
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Drug Preparation and Randomisation 
Each capsule contained either 100mg of caffeine (No Doz) and gluten-free 
cornflower filler, or only gluten-free cornflower. All capsules were indistinguishable, 
equivalent in weight, shape, colour and size, blinding participants and experimenters to 
the drug condition. The caffeine drug condition included two capsules for a total of 
200mg caffeine, an optimal dose for low caffeine consumers (Brunye et al., 2010a). 
While the placebo condition included two capsules of gluten-free cornflower. 
Randomisation and counterbalancing of drug condition were conducted independently 
of experimental researchers. Prior to participant recruitment, capsules were packaged in 
identical envelopes by a chief researcher according to a counterbalanced drug 
presentation sequence. To complete the double-blind, the chief researcher in question 
remained absent during experimental sessions.  
Procedure  
Eligible participants were invited to the UTAS Cognitive Neuroscience Lab for 
two experimental sessions of approximately two-and-a-half hours. All sessions began at 
approximately 1pm and were separated by at least one week. On arriving for the first 
session, each participant was given an information sheet and consent form (see 
Appendix D). Participants were then setup with EEG recording equipment and relocated 
to an adjacent room and seated at eye line with the centre point of a computer screen. 
Participants were briefed on the upcoming computer task, either the ANT or Flanker 
Task (not discussed in the present study). Participants were asked to respond to each 
trial as quickly and accurately as possible while limiting eye and body movements. 
Computer tasks were presented in counterbalanced order across participants and took 
approximately forty-five minutes to complete. Immediately after the computer tasks, 
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pre-ingestion measures (POMS, KSS, VAS-performance) were completed, and the EEG 
Quik-Cap was temporarily disconnected. Each participant was provided with a glass of 
water (250mL) and an envelope containing two of either caffeine (200mg) or placebo 
capsules. A thirty-minute break began once the capsules had been ingested, enough time 
for plasma caffeine concentration to peak (Adan et al., 2008). During the break 
participants completed the WTAR and experimental questionnaire, followed by a 
relaxation period. The computer tasks were completed for a second time (same order), 
followed by post-ingestion measures (POMS, KSS, VAS-performance, VAS-drug 
effects, blinding check), and a disassembling of the EEG Quik-Cap. Upon completion 
of the second session (1st session repeated, but with alternate drug condition) 
participants were debriefed, and compensated for out-of-pocket expenses (gift voucher 
and/or course credit).  
Design and Data Analysis  
Behavioural measures included RT (ms) and accuracy (% correct responses) 
scores from the ANT. False starts (i.e., RTs <150ms) and extraordinarily slow responses 
(>3 SDs) were removed from the dataset. Accuracy data was only reported for main 
effects and interactions with statistical significance (p<.05) and theoretical relevance 
(e.g., speed-accuracy trade-off). Planned pairwise comparisons were conducted for RT 
and accuracy to measure the effect of Drug across Cue, Flanker and Time.  
To investigate the effect of caffeine on behavioural measures of alerting, 
orienting and executive control networks, a 3 (Cue: No Cue, Central Cue Spatial Cue) x 
2 (Flanker: Congruent, Incongruent) x 2 (Drug: Placebo, Caffeine) x 2 (Time: Pre-
ingestion, Post-ingestion) repeated measures ANOVA was initially conducted for RT 
and accuracy. Attentional networks were then calculated for RT by generating an 
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averaged difference between No Cue and Central Cue (Alerting), Central Cue and 
Spatial Cue (Orienting), and Congruent and Incongruent Flankers (Executive Control) 
for placebo and caffeine scores at post-ingestion. A 2 (Drug; Placebo, Caffeine) x 3 
(Network; Alerting, Orienting, Executive Control) repeated measures ANOVA was 
conducted, and planned pairwise comparisons subsequently performed.  
To investigate the effect of caffeine on electrophysiological measures of alerting 
and orienting, a 3 (Cue: No Cue, Central Cue Spatial Cue) x 2 (Flanker: Congruent, 
Incongruent) x 2 (Drug: Placebo, Caffeine) x 2 (Time: Pre-ingestion, Post-ingestion) 
repeated measures ANOVA was conducted for the peak amplitude (µV) of the N1 ERP 
component and pairwise comparisons performed. The N1 amplitude was analysed at the 
occipital midline (Oz) electrode site. Electrophysiological (EEG) analysis excluded 
three datasets due to EEG malfunction. To account for the missing ERP data, a mixed-
models ANOVA was performed, revealing no deviation from the initial ANOVA. With 
respect to the principle of parsimony (Epstein, 1984), results reported in the present 
study were generated from the repeated-measures ANOVA output.  
To investigate the effect of caffeine on subjective reports of mood and 
sleepiness, 2 (Drug: Placebo, Caffeine) x 2 (Time: Pre-ingestion, Post-ingestion) 
repeated measures ANOVAs were conducted across the POMS-SF subscales and KSS 
ratings. Baseline checks for recent caffeine intake, sleep, sleepiness (KSS), subjective 
performance (VAS), and POMS-SF subscales were assessed between drug conditions 
via paired-samples t-tests. Post-ingestion manipulation checks, including subjective 
drug effects (VAS) and caffeine ingestion confidence (0-100%), were assessed with a 
paired-samples t-test and Related-Samples Wilcoxon signed Rank Test, respectively. 
Assumptions of ANOVA were checked to determine the appropriateness of each 
dataset for further analysis. The assumption of sphericity was likely violated for 
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interactions and effects involving Cue and Network (3 levels). Greenhouse-Geisser 
corrected output was subsequently reported for effects involving Cue and Network. 
Interactions were only reported with statistical significance (p<.05) and/or theoretically 
relevance. Bonferroni corrections were applied to tests of simple main effects. With 20 
participants, the present study fell slightly short of initial power estimates (24 
participants). Subsequently, the utility of the p-value was somewhat diminished 
(Durlak, 2009). However, effect sizes are not as vulnerable to low statistical power as p-
values, and subsequently were essential for interpretation of the present findings.  
In the current study, partial eta squared (ηp2), the amount of variance in a 
dependent variable able to be explained by an independent variable (Cohen, 1973), was 
used to indicate the effect sizes for omnibus ANOVAs. Effect sizes for ηp2 were 
interpreted according to Cohen’s (1988) guidelines, with 0.01=small, 0.06=medium, 
and 0.14=large. Hedge’s g corrects for bias within small samples (Lakens, 2013), and 
was therefore applied to tests of simple effects, with effect sizes interpreted as 
0.2=small, 0.5=medium, and 0.8=large (Cohen, 1992). 
Results 
Demographic and Screening Variables 
Descriptive statistics for demographics and questionnaire measures can be 
viewed in Table 2. All participants reported low-to-no caffeine consumption (0-
150mg/day), were predominantly university educated, within the normal-superior range 
of intelligence (WTAR), and not underweight (BMI). Participants were not problematic 
alcohol consumers (AUDIT), and not highly distressed (K10).  
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Table 2 
Demographic and Screening Variables 
Variable M (SD) Range 
Age (Years) 22.10 (2.99) 19-29 
Education (% completed Grade 12) 95% 11-12 
Education (% present/post-university)  75% NA 
Handedness (% right-handed) 95% NA 
Body Mass Index (BMI) 24.4 (3.91) 19-34 
Alcohol Use (AUDIT) 4.20 (3.75) 0-15 
Psychological Distress (K10) 14.50 (2.61) 10-20 
General Intelligence Estimate 
(WTAR) 
112.45 (7.37) 97-124 
Caffeine Consumption (mg/day) 45.69 (38.47) 0-144 
Note: M= Mean, SD= Standard Deviation 
 
Baseline Measures and Manipulation Check 
A comparison of participants at baseline on potentially confounding variables 
are presented in Table 3. For placebo and caffeine conditions no significant differences 
were seen for caffeine intake, sleep, and subjective ratings of sleepiness, alertness. 
Comparisons made at post-ingestion are therefore likely to reflect drug effects. 
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Table 3  
Comparison of Baseline Variables Between Placebo and Drug Conditions  
Baseline Measures Placebo 
M (SD) 
Caffeine 
M (SD) 
t 
(1,19) 
p g 
Caffeine Intake (per 100mg) .11 (.32) .11 (.32) NA NA NA 
Sleep (Hours) 8.04 (1.35) 7.60 (2.1) 1.099 .286 0.24 
Sleepiness (KSS) 5.90 (1.37) 5.60 (1.47) 1.031 .316 0.17 
Alertness (VAS) 3.24 (1.86) 3.01 (1.80) .576 .571 0.12 
Note: M=Mean, SD=Standard Deviation  
 
Participants reported significantly higher confidence (0-100%) in having 
ingested caffeine when in the active condition (M=64.63, SD=26.33) than the placebo 
condition (M=29.55, SD=31.45), as measured by a Related-Samples Wilcoxon signed 
Rank Test, Z=2.758, p=.006. Caffeine confidence scores were highly variable for both 
the active (range=10-100%) and placebo conditions (range=0-80%). Perceived effects 
of drug (as measured by the VAS-Drug Effects) were significantly higher following 
caffeine (M=5.12, SD=1.62) compared with placebo (M=2.87, SD=1.88), t(18)=3.765, 
p<.001, g=1.26. 
Mood and Sleepiness 
Descriptive statistics for mood (POMS-SF) and sleepiness (KSS) for Drug x 
Time are displayed in Table 4. A series of 2x2 repeated measures ANOVAs revealed a 
significant Drug x Time interaction for Confusion-Bewilderment, F(1,18)=5.268, 
p=.033, ηp2=.21. Confusion-Bewilderment decreased significantly from pre-ingestion 
compared to post-ingestion following caffeine, p=.006, g=0.75. Following placebo, 
Confusion-Bewilderment was not significantly different from pre-ingestion to post-
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ingestion, p=.881, g=0.03. At pre-ingestion, Confusion-Bewilderment was not 
significantly different between caffeine and placebo, p=.343, g=0.21. While at post-
ingestion, Confusion-Bewilderment was significantly less for caffeine compared with  
placebo, p<.001, g=0.92. 
 
 
 
Table 4 
Means (SD) for Mood (POMS-SF) and Sleepiness (KSS) at Pre- and Post-Ingestion 
  Placebo  Caffeine 
  Pre Post  Pre Post 
POMS Subscales       
Depression-Dejection  1.29 (0.53) 0.57 (0.27)  1.24 (0.49) 0.14 (.10) 
Tension-Anxiety  2.76 (0.56) 2.14 (0.55)  2.33 (0.59) 2.43 (0.52) 
Anger-Hostility  .91 (0.32) 0.52 (0.21)  0.52 (0.26) 0.24 (0.19) 
Vigour-Activity  5.47 (0.98) 4.33 (0.82)  4.91 (0.78) 7.29 (1.18) 
Fatigue-Inertia  6.05 (0.59) 7.00 (0.86)  5.00 (0.74) 3.86 (0.79) 
Confusion-
Bewilderment 
 1.71 (0.28) 1.76 (0.33)  1.52 (0.27) 0.71 (0.30) 
Sleepiness (KSS)  5.78 (1.31) 5.84 (1.60)  5.52 (1.46) 4.36 (1.53) 
Note: Pre and Post refer to pre-ingestion and post-ingestion. The KSS ranged from 1-9; 
higher ratings correspond to greater levels sleepiness. Confusion-Bewilderment ranged 
from 0-20. Fatigue-Inertia from 0-20, Vigour-Activity from 0-24, Anger-Hostility from 
0-28, and Depression-Dejection from 0-32; higher ratings correspond to greater levels 
of indicated mood.  
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A Drug x Time interaction for Vigour-Activity was also found, F(1,18)=7.589, 
p=.012, ηp2=.275. Vigour-Activity significantly increased from pre-ingestion to post-
ingestion following caffeine, p=.010, g=0.60. Following placebo, Vigour-Activity was 
not significantly different from pre-ingestion to post-ingestion, p=.065, g=0.27. At pre-
ingestion, Vigour-Activity was not significantly different between caffeine and placebo, 
p=.343, g=0.15. While at post-ingestion, Vigour-Activity was rated as significantly 
higher following caffeine compared with placebo, p=.028, g=0.73.  
A trending toward significant Drug x Time interaction was found for Fatigue-
Inertia, F(1,18)=3.958, p=.060, ηp2=.165. No significant difference in Fatigue-Inertia at 
pre-ingestion compared to post-ingestion for either caffeine, p=.168, g=0.31, or placebo, 
p=.309, g=0.21. At pre-ingestion, Fatigue-Inertia was not significantly different 
between caffeine and placebo, p=.237, g=0.39. While at post-ingestion, Fatigue-Inertia 
was rated as significantly higher following placebo compared with caffeine, p=009, 
g=0.81.  
Analysis of sleepiness (KSS) revealed a significant Drug x Time interaction, 
F(1,18)=5.267, p=.034, ηp2=.226. Following caffeine, ratings of sleepiness significantly 
reduced from pre-ingestion to post-ingestion, p=.008, g=0.75. For placebo, sleepiness 
ratings did not significantly differ from pre-ingestion to post-ingestion, p=.841, g=0.03. 
At pre-ingestion, ratings of sleepiness were not significantly different between the 
caffeine and placebo conditions, p=.316, g=0.26. At post-ingestion, sleepiness ratings 
significantly reduced with caffeine compared to placebo, p=.011, g=0.92.  
Reaction Time  
 
Descriptive statistics for RT (milliseconds) across Drug, Cue, Congruency, Drug 
and Time can be viewed in Table 5. The effect of Cue on RT was statistically 
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significant and large in magnitude, F(2,19)=350.634, p<.001, ηp2=.949. Pairwise 
comparisons showed that overall, the spatial cue was significantly faster than the central 
cue, which was significantly faster than no cue, p<.001 for each comparison.  
 
The main effect of Drug was not statistically significant, F(1,19)=3.735, p=.068, 
ηp2=.164. However, a trend toward statistical significance and a large magnitude of 
effect was evidenced for the two-way Drug x Time interaction F(1,19)=3.581, p=.074 
Table 5  
Averaged Reaction Times (ms) Across Drug, Flanker, Cue and Time.   
      Pre-Ingestion  Post-Ingestion 
Drug Flanker  Cue  M SD  M SD 
Placebo Congruent  No Cue  492.26 38.59 493.57 40.19 
   Central  469.11 43.17 462.15 40.55 
 Spatial  424.35 39.00 423.28 36.48 
Incongruent  No Cue  563.48 36.34 562.87 42.19 
  Central  549.90 46.08 548.18 45.14 
 Spatial  489.16 36.51 491.74 37.75 
Caffeine Congruent  No Cue  484.23 36.21 474.77 37.46 
   Central  463.71 40.07 446.97 42.39 
 Spatial  422.20 36.69 405.43 33.92 
Incongruent  No Cue  558.27 44.43 543.29 44.17 
  Central  549.79 50.08 530.94 44.44 
 Spatial  486.25 44.15 463.63 41.30 
Note: M= Mean, SD= Standard Deviation 
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ηp2=.159 (see Figure 2). Pairwise comparisons indicated significantly reduced RTs 
following caffeine compared to pre-ingestion, p=.004, g=0.42. While RTs following 
placebo did not significantly differ from RTs at pre-ingestion, p=.866, g=0.03. At post-
ingestion, RTs were significantly faster following caffeine than placebo, p=.001, 
g=0.51. While at pre-ingestion, RTs did not significantly differ between caffeine and 
placebo conditions, p=.676, g=0.07.  
 
Figure 2. Overall reaction time (ms) at pre- and post-ingestion following caffeine and 
placebo (error bars represent 95%CIs).    
 
The hypothesised Drug x Time x Cue interaction was not significant, 
F(2,38)=2.091, p=.140, ηp2=.099. However, a trend toward significance and a moderate 
effect size warranted further analysis (see Figure 3). Across Cues, a significant effect of 
Drug was found at post-ingestion, F(3,17)=7.174, p=.003, ηp2=.56, but not at pre-
ingestion, F(3,17)=0.593, p=.626, ηp2=.095. Planned pairwise comparisons revealed that 
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at post-ingestion, No Cue trials were responded to significantly faster (RT) following 
caffeine than placebo, p=.004, g=0.48. Response times for Central Cue trials were also 
significantly faster following caffeine than placebo, p=.006, g=0.39. While RTs for 
Spatial Cue trials were also significantly faster with caffeine compared with placebo, 
p<.001, g=0.62. At pre-ingestion, there were no significant differences between placebo 
and caffeine conditions for each of the Cues (p >.05). 
 
 
Figure 3. Reaction Time (ms) following each Cue at pre-ingestion and post-ingestion 
with caffeine and placebo (error bars represent 95%CIs).   
 
Across Cues, a significant effect of Time was also found for caffeine, 
F(3,17)=6.858, p=.003, ηp2=.55, but not placebo, F(3,17)=0.623, p=.610, ηp2=.10. A 
small effect suggested RTs on No Cue trials in the caffeine condition were faster at 
post-ingestion than at pre-ingestion, p=.051, g=0.31. For Central Cues, RTs were 
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significantly faster in the caffeine condition at post- than at pre-ingestion, p<.001, 
g=0.42. For Spatial Cues, RTs were significantly faster with caffeine at post- than at 
pre-ingestion, p<.001, g=0.51. For each Cue RTs did not significantly differ from pre- 
to post-ingestion following placebo (all >.05).  
A three-way Drug x Time x Flanker interaction was significant, F(1,19)=6.159, 
p=.023, ηp2=.245 (See Figure 4). For congruent trials, RTs were significantly faster 
following caffeine than placebo, p=.002, g=0.47. While at pre-ingestion, RTs for 
caffeine did not significantly differ from placebo, p=.544, g=0.14. From pre-ingestion to 
post-ingestion RTs were significantly faster following caffeine, p=.010, g=0.38, but not 
placebo, p=.726, g=0.06.  
 
 
Figure 4. Reaction Time (ms) following each Flanker at pre-ingestion and post-
ingestion with caffeine and placebo (error bars represent 95%CIs).    
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For incongruent trials, RTs were significantly faster following caffeine 
compared with placebo, p=.002, g=0.53. While at pre-ingestion, RTs for caffeine did 
not significantly differ from placebo, p=806, g=0.06. From pre-ingestion to post-
ingestion RTs were significantly faster following caffeine, p=.002, g=0.42, but not 
placebo, p=.726, g=0.01. 
The hypothesised Drug x Network interaction trended toward significance and 
was analysed, F(1.49,28.25)=2.404, p=.121, ηp2=.112 (see Figure 5). Pairwise 
comparisons with Bonferroni correction (α=.017) showed Alerting effects were not 
significantly different between placebo (M=23.05, SD=11.39) and caffeine (M=20.01, 
SD=12.43), p=.450, g=0.25.  
 
Figure 5. Difference scores (ms) for caffeine and placebo at post-ingestion (error bars 
represent 95%CIs). Note that higher difference scores for Alerting and Orienting 
indicate a greater effect, while lower difference scores for Executive Control indicate a 
greater effect.  
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Orienting effects were not significantly greater for caffeine (M=54.43, 
SD=13.39) than placebo (M=47.66, SD=18.52), p=.023. A small-medium effect size 
indicated a meaningful difference was found, g=0.41. Executive Control effects were 
not significantly different between placebo (M=74.59, SD=19.8) and caffeine (M=70.23, 
SD=23.24), p=.280, g=0.19. 
Accuracy  
The hypothesised Drug x Cue x Time interaction was non-significant, 
F(1,18)=.826, p=.45, ηp2=.04. However a significant Drug x Time interaction was 
found, F(1,19)=4.800, p=.041, ηp2=.20 (see Figure 6). At post-ingestion, accuracy was 
significantly greater following caffeine (M=96.95, SD=1.44) than placebo (M=94.77, 
SD=3.68), p=.012, g=0.76. While at pre-ingestion accuracy did not differ significantly 
between caffeine and placebo, p=.867, g=0.03.  
 
Figure 6. Accuracy (% correct responses) at pre-ingestion and post-ingestion following 
placebo (left) and caffeine (right; error bars represent 95%CIs).    
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Pairwise comparisons revealed a significant increase in accuracy for caffeine at 
post-ingestion (M=96.95, SD=1.44) compared to pre-ingestion (M=95.74, SD=2.38), 
p=.023, g=0.60, and a non-significant difference from pre-ingestion (M=95.83, 
SD=2.99) to post-ingestion (M=94.77, SD=3.68) following placebo, p=.145, g=0.31. 
N1 Amplitude 
Electrophysiological (EEG) analysis excluded three datasets due to EEG 
malfunction. The grand mean waveforms (μV) generated at the midline occipital (Oz) 
electrode site can be viewed for caffeine and placebo at Figures 7 and 8, respectively. 
The averaged grand mean waveform for N1-Oz peaked at approximately 160ms post-
stimulus.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Grand averaged N1 ERP amplitude for Caffeine at midline occipital electrode 
(Oz) following each Cue at pre- and post-ingestion.  
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Figure 8. Grand averaged N1 ERP amplitude for Placebo at midline occipital electrode 
(Oz) following each Cue at pre- and post-ingestion. 
 
The effect of caffeine on the N1 ERP component is visually apparent for No 
Cue, at which the reduction in amplitude (μV) from pre-ingestion to post-ingestion seen 
for placebo does not occur for caffeine. Otherwise, caffeine and placebo did not appear 
to have any obvious distinctions. 
Descriptive statistics for N1 amplitude across Drug, Cue and Time are shown in 
Table 6. The hypothesised Drug x Cue x Time interaction was non-significant, 
F(2,32)=.090, p=.914, ηp2=.006. However, the Drug x Time interaction was significant, 
F(1,16)=8.988, p=.009, ηp2=.359 (see Figure 9). 
N1 
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Table 6  
N1 ERP Amplitude for Each Cue at Pre-ingestion and Post-Ingestion   
 Placebo  Caffeine 
 Pre 
M (SD) 
Post 
M (SD) 
 Pre 
M (SD) 
Post 
M (SD) 
      
No Cue -0.99 (1.76) -0.31 (2.27)  -0.96 (2.68) -1.04 (2.19) 
Central Cue -1.44 (3.06) -0.62 (2.03)  -1.17 (3.01) -1.39 (2.84) 
Spatial Cue -4.36 (3.05) -3.76 (2.56)  -3.76 (2.76) -3.91 (2.73) 
Note: M=Mean, SD=Standard Deviation.  
 
 
Figure 9. Grand averaged N1 ERP amplitude (μV) for Placebo and Caffeine at midline 
occipital electrode (Oz) at pre- and post-ingestion.  
Analysis of main effects revealed significance for Cue, F(2,32)=.42.68, p<.001, 
ηp2=.73, indicating a significantly greater overall amplitude for Spatial Cue (M=-3.95, 
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SD=1.37) relative to Central Cue (M=-1.16, SD=2.48) and No Cue (M=-.83, SD=2.05), 
p<.001, g=1.36, p<.001, g=1.65, respectively. Central and No Cue conditions were not 
significantly different, p=.351, g=0.14. Following placebo, amplitude (μV) at post-
ingestion was significantly reduced from pre-ingestion, p=.002, g=0.46. While for 
caffeine, no significant difference was seen from pre-ingestion to post-ingestion, 
p=.536, g=0.09. At pre-ingestion and post-ingestion, no significant differences in 
amplitude occurred between placebo and caffeine, p=.429, g=0.18, p=.140, g=0.26, 
respectively.  
Discussion 
The present study examined the acute effects of caffeine (200mg) on 
behavioural (RT & accuracy) measures of alerting, orienting and executive control, and 
the electrophysiological (N1 ERP component) measures of alerting and orienting with 
healthy, low caffeine consumers. As hypothesised, RT decreased following caffeine 
compared with placebo, across cue and flanker conditions. Accuracy scores across cue 
and flanker conditions also improved following caffeine compared with placebo, as 
expected. Congruent and incongruent trials were also significantly faster following 
caffeine compared with placebo. While the prediction that caffeine would exert a 
greater effect upon the alerting and executive control networks was partially supported. 
A non-significant but meaningful group orienting effect was shown, somewhat contrary 
to expectation.  
The prediction that the N1 amplitude would be smallest for no cue, greater for 
central cue, and greatest for spatial cue was partially supported. The hypothesis that for 
each cue the N1 amplitude would be significantly greater following caffeine compared 
with placebo was not supported. However, a significant Drug x Time interaction 
showed a significant reduction in N1 amplitude following placebo not seen for caffeine. 
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Taken together, these results suggest the improved RTs following caffeine for each cue 
and flanker type were not reflective of an effect of caffeine upon the alerting, orienting, 
or executive control networks. Rather, the improved scores on all aspects of the ANT 
following caffeine appear to primarily reflect a maintenance of tonic alertness and 
sustained attention.  
Behavioural Measures of Attention 
 Evidence for the efficacy of the ANT was found, with a significant overall effect 
of Cue, whereby the spatial cue elicited faster RTs than the central cue, which elicited 
faster RTs than no cue (Fan et al., 2002). Within a significant Drug x Time x Flanker 
interaction, congruent flanker trials were also shown to be significantly faster than 
incongruent trials. A Drug x Time interaction trending toward significance showed an 
overall improvement in RT following caffeine compared with placebo. A non-
significant and trivial difference between RT scores at pre-ingestion between placebo 
and caffeine conditions provided additional evidence for the efficacy of making 
comparisons between placebo and caffeine at post-ingestion. The hypothesised Drug x 
Time x Cue interaction trended toward significance and warranted further inspection. 
For each Cue condition RTs were faster following caffeine than placebo. Congruent and 
incongruent Flanker trials were shown to be significantly faster following caffeine 
compared with placebo, as indicated by a significant Drug x Time x Flanker interaction. 
A significant Drug x Time interaction for accuracy showed the percentage of correct 
responses both decreased following placebo and increased following caffeine. Taken 
together, these results strongly support the numerous previous studies showing an acute 
enhancement of attention following caffeine (Einöther & Giesbrecht, 2013; McLellen et 
al., 2016; Smith, 2002).  
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 The specific contribution of each attentional mechanism following caffeine is 
less clear. The hypothesised Drug x Network interaction trended toward significance 
and warranted further analysis. However, after Bonferroni corrections were applied, no 
significant difference was seen between caffeine and placebo regarding alerting, 
orienting or executive control effects. This suggests the overall enhancement in RT 
following caffeine predominantly reflected a specific effect of caffeine upon tonic 
alertness. However, a significant Drug x Time x Flanker interaction also qualified a 
differential executive control effect, whereby trials containing incongruent flankers 
were responded to faster than congruent flankers from pre-ingestion to post-ingestion. 
The difference between placebo and caffeine was non-significant for the orienting 
network. However, a small-medium effect size (g=0.41) suggested that the orienting 
network was positively impacted by caffeine. 
Giles et al. (2012) also found no significant effect of caffeine upon phasic 
alertness or orienting but did find a significant effect upon executive control. This same 
result was found in a follow up study (Giles et al., 2016). These results were suggested 
to mean caffeine did not influence early visual attention beyond improvements to 
general arousal and sustained attention (Giles et al., 2012). More specifically, it might 
be that a phasic alerting effect did not result because; a) the warning cue contains a 
ceiling effect, whereby general arousal (and subsequent performance) can only be 
elevated in response to the waring cue so far before performance is diminished, and b) 
the response readying effect of the warning cue is subsumed by the effect of caffeine 
upon tonic alerting. This explanation draws from previous work showing both the 
warning cue and caffeine can generate neural activation in the midbrain-thalamus-ACC 
network and pre-SMA, the same brain regions involved during tests of tonic alertness 
(Fan et al., 2005; Yanaka et al., 2010). 
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An alternate explanation for not finding a phasic alerting effect is that the 200mg 
dose of caffeine was too low. Some participants reported no caffeine consumption, 
while others reported both regular and fluctuating caffeine consumption (<150mg/day). 
James (2014) has argued that regular low use of caffeine, even as low as 70mg/day, can 
promote the up-regulation of adenosine receptors and subsequent tolerance and 
withdrawal effects. It was also argued that caffeine consumption is underreported due to 
its inconspicuous presence as an ingredient in numerous products. Subsequently, true 
phasic alerting effects of caffeine may have been masked by a low-level tolerance. This 
point is made particularly salient when considered in relation to the significant phasic 
alertness effect previously demonstrated by low caffeine consumers following a 200mg 
dose (Brunye et al., 2010a).  
The effect of caffeine on the orienting network was not significantly different 
from placebo. However, a small-medium effect size (g=0.41) suggested that the 
orienting network was positively impacted by caffeine. Literature pertaining to orienting 
effects is scarce and limited and determining the effect of caffeine upon the orienting 
network is ongoing (McLellen et al., 2016). The current finding of a small-medium 
effect may have reflected a shared reliance on acetylcholine for tonic alertness and 
orienting, and the adenosine-antagonistic action of caffeine at prefrontal, frontoparietal, 
somatosensory, hippocampal, and visual cortices (Carter, 1995; Klinkenberg et al., 
2010).  
Studies that did not find a differential effect of caffeine upon the orienting 
network may have suffered from a lack of trials specifically assessing orienting. The 
present study utilised an ANT with 160 trials that specifically measured orienting, while 
previous studies used an ANT with 72 (Brunye et al., 2010a, 2010b; Giles et al., 2012; 
Giles et al., 2016). Results of previous studies could also reflect the shorter duration of 
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the ANT used; approximately 15 minutes compared to 28 minutes for the present study. 
The effects of caffeine upon the cholinergic system, and subsequent tonic alertness and 
orienting, might only be revealed over longer durations. However, the effect of 
orienting over-and-above tonic alertness was not significant following caffeine (despite 
the small-medium effect), and additional research is needed to determine the effect of 
caffeine upon the orienting network.  
 A significant Drug x Time x Flanker interaction suggested an executive control 
effect, whereby the difference in RT from pre-ingestion to post-ingestion for caffeine 
(but not placebo) was greater for congruent trials than incongruent trials. Put simply, 
caffeine appeared to improve the ability of an individual to inhibit distractive stimuli. 
This finding supports results of previous work (Brunye et al., 2010a, 2010b; Giles et al., 
2012), but not all (Tieges et al., 2007). This pattern of results is thought to reflect 
caffeine as an adenosine antagonist and the consequent innervation of densely 
dopaminergic brain regions associated with executive functioning, such as the ACC and 
lateral prefrontal cortices (Fan et al., 2005). 
Electrophysiological Measures of Attention 
Neuhaus et al. (2010) showed a significant difference between no cue, central cue 
and spatial cue trials on the N1 ERP amplitude, whereby amplitude increased 
significantly with cue informativity. The present study did not find this pattern of results 
for placebo or caffeine conditions at either pre-ingestion or post-ingestion. The present 
study did show an increase in N1 amplitude from no cue and central cue to spatial cue 
for both caffeine and placebo conditions, but not from no cue to central cue. The pattern 
of results seen previously could be attributed to averaging across several electrode sites 
(Neuhaus et al., 2010), rather than specifically targeting an electrode at occipital midline 
(Oz). A significant Drug x Time interaction (p=.009, ηp2=.359) showed an overall 
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significant reduction in amplitude did occur from pre-ingestion to post-ingestion 
following placebo. Considering this same drop in amplitude was not seen following 
caffeine, caffeine may have prevented this decline in amplitude, subsequently playing a 
role in the improved RT and accuracy scores.  
The maintenance of cortical activity seen following caffeine provides evidence for 
an enhancement of sustained attention (Fu et al., 2005; Padilla et al., 2006). This finding 
aligns with work from Foxe et al. (2012) who monitored EEG activity during a SRT 
task following caffeine. Caffeine was found to significantly reduce the presence of 
alpha-band oscillations, an index of fatigue, compared to placebo. Caffeine seemingly 
prevented the normal decrease in cortical activity typically seen during lengthy, fatigue-
inducing tasks (Pfurtscheller, 1992). Results of the present study also parallel with 
conceptions of caffeine as an adenosine modulator within the CNS, blocking adenosine, 
and sustaining overall neural activity (Urry & Landolt, 2014). The visually apparent 
reduction in amplitude on no cue trials from pre-ingestion to post-ingestion following 
placebo potentially supports this view, as no cue trials provide an index of tonic 
alertness. However, high variability in the N1 ERP dataset for Drug x Time x Cue 
suggests greater power is required to determine whether the significant Drug x Time 
interaction does extend to specific cues more so than others.  
A significant Drug x Time x Flanker interaction for RT suggested the executive 
control network was differentially affected by caffeine than placebo. However, the 
present study was unable to determine whether the significant Drug x Time interaction 
for the ERP amplitude extended out to response inhibition. Executive functioning has 
been consistently indexed by N2 and P3 ERP components at frontal electrode sites 
(Neuhaus et al., 2010). However, few previous studies have examined the effect of 
caffeine upon ERP correlates of response inhibition (Barry et al., 2014; Kok et al., 
45 
 
 
2004). While beyond the scope of the present study, future research that incorporates 
the N2 and P3 ERP components could provide valuable insights into the effects of 
caffeine upon neural correlates of response inhibition.  
Mood, Fatigue, and Sleepiness 
 Drug x Time interactions for confusion-bewilderment (POMS-SF), vigour-
activity (POMS-SF), fatigue-inertia (POMS-SF), and sleepiness (KSS) suggested 
several effects of caffeine upon mood and sleepiness. Following caffeine, participants of 
the present study reported significantly less symptoms of confusion compared with 
placebo. This can potentially be explained by the enhancement in response inhibition, 
and/or vice-versa (McLellen et al., 2016). Following caffeine, vigour-activity increased 
and sleepiness decreased, indicative of elevated enthusiasm and task readiness. These 
findings align with evidence showing an overall increase in general arousal and tonic 
alertness (Giles et al., 2016). Level of fatigue-inertia increased following placebo but 
was maintained with caffeine. This supports discussion points regarding the Drug x 
Time interaction for the N1 ERP amplitude, whereby the reduction in cortical activity at 
the occipital N1 following placebo, not seen following caffeine, was indicative of 
fatigue prevention (Pfurtscheller, 1992).  
Practical Implications 
 Findings of the present study suggest caffeine enhances attentional capability in 
healthy, low consumers of caffeine, particularly for tasks requiring extended tonic 
alertness and response inhibition. This cognitive enhancement occurred without a 
speed-accuracy trade-off. Present results show a significant increase in accuracy 
following caffeine compared to placebo. Examples of tasks requiring efficient tonic 
alertness and response inhibition are numerous, and include driving, police stakeouts, 
scientific research, to name a few.  
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Present findings may also benefit research into age-related diseases such as 
Alzheimer’s disease (Jeong, 2004; Panza et al., 2015). Alzheimer’s disease (AD) is 
characterised by slowed mean EEG frequency, less complex cortical activity, and 
reduced coherences among cortical regions (Jeong, 2004). The present 
electrophysiological results suggest caffeine might prevent reductions in neural activity 
associated with sustained attention. Given present findings, EEG could provide a 
beneficial means of investigating the effects of caffeine upon symptoms of AD (Jeong, 
2004; Panza et al., 2015).  
Limitations 
Post-ingestion manipulation checks indicated that participants were significantly 
more confident in having just experienced the effects of caffeine following the active 
condition than the placebo condition. This could have potentially resulted in drug 
expectancy effects, whereby following the placebo session, participants could return for 
their second session expecting to have caffeine, and subsequently act according to 
preconceptions about its attentional enhancing effects (Huntley & Juliano, 2012; Kirsch, 
1997). Following the caffeine session, participants could have returned for their second 
session expecting to receive a placebo. Considering the duration of the ANT task, along 
with the confidence that the task would not be supplemented with caffeine, enthusiasm 
and subsequent effort for the ANT at post-ingestion could have been impacted (Kirsch, 
1997). The non-significant differences in RT at pre-ingestion and large variability in 
caffeine confidence scores goes someway to refute the impact of drug expectancy 
effects on present results. However, future studies could include a baseline caffeine 
confidence check as an added precaution.  
The present study also could have accounted for personality as a potentially 
confounding factor. Performance enhancing effects of caffeine have been shown to be 
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more pronounced for individuals high in extraversion, impulsivity, and novelty seeking 
than individuals high in introversion (Anderson, 1994; Gurpegui et al., 2007). These 
results have been attributed to lower levels of dopamine in high extraverts relative to 
high introverts (Gurpegui et al., 2007).  
Conclusion 
 Considering the prevalence of caffeine consumption, it is essential to understand 
the effects of caffeine on attention and associated neural processes.  Results of the 
present study add to the increasing body of literature showing that caffeine can be used 
as a cognitive enhancement on tasks of visual attention, particularly sustained attention 
and response inhibition. Not only furthering the literature pertaining to behavioural 
indices of attention, the present study appears to be the first to assess the effect of 
caffeine upon the visual N1 ERP component using an ANT.  
More specifically, the attentional mechanisms effected by caffeine, at least for 
healthy, low consumers following a dose of 200mg caffeine, include the tonic alertness 
component of the alerting network and the response inhibition component of the 
executive control network. The significant improvements in RT and accuracy appear to 
primarily reflect an effect of caffeine on general arousal and tonic alertness, whereby 
attentional processing was maintained during the ANT following caffeine and not 
placebo. This view is supported by current electrophysiological findings which showed 
a decline in cortical activity at the occipital N1 component following placebo but not 
caffeine. Given the popularity of caffeine worldwide, these results carry meaningful 
implications regarding CNS functioning, and the way in which individuals choose to 
attend to and process information. 
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Appendix B 
Experimental session questionnaire 
Date ____/____/____       Participant ID 
_____________ 
 
1. Check that participant has abstained from alcohol for 24 hours and illicit drug use since 
completing the screening questionnaire 
2. Weight ___________ kg 
Height____________ cm 
BMI _____________ 
3. Have you consumed any medications in the past week (or any prescribed medications 
since completing the screening questionnaire)? 
If yes, please detail:  
4. How many cups of coffee (or any other caffeinated drinks/products) have you 
consumed today? _____  
If > 0. How many hours since your last caffeinated drink ______ hours 
5. Have you had any tobacco or nicotine products today? Yes / No  
If yes, how many cigarettes (or nicotine products) have you had today? ____ 
If yes, How many hours since your last cigarette (nicotine product) ______ hours 
6. What have you had to eat today? How long since you last ate something? _____mins 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________  
7.  Approximately how many hours sleep did you have last night? ____ 
 
Medication Number of 
occasions 
Time since last used Estimated dose 
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Appendix C 
Participant Code:               
Test Point: pre/post 
 
Visual Analogue Scales of Subjective Performance 
Please mark on each line at the point which most accurately reflects your level 
of agreement AT THE MOMENT with the below statement: 
 
1. I feel alert 
STRONGLY  
AGREE 
 STRONGLY  
DISAGREE 
 
2. I feel that I will be able to perform the attention tasks to the best of my ability 
STRONGLY 
 AGREE 
 STRONGLY  
DISAGREE 
 
3.I do not feel that my driving would be impaired right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
 
4.I feel capable of driving safely right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
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Visual Analogue Scales of Subjective Drug Effects 
 
Participant number:          
Test point: post  
Please mark on each line at the point which most accurately reflects your level 
of agreement AT THE MOMENT with the below statement: 
 
1. Strength of drug effect 
NO EFFECT 
 
 VERY 
STRONG 
EFFECT 
2. Liking of the drug effect 
DISLIKE VERY 
MUCH 
 
 LIKE VERY 
MUCH 
3. Alert level 
NOT ALERT 
 
 VERY ALERT 
4. Intoxication 
NOT 
INTOXICATED 
 
 VERY 
INTOXICATED 
 
How sure are you out of 100% that you have taken caffeine today?_____________________ 
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Appendix D 
ID Number___________ 
INFORMATION SHEET 
 
The Effect of Caffeine on Attentional Networks 
 
Chief Investigators: Dr Allison Matthews & Assoc. Prof. Raimondo Bruno 
Researchers:  [Add student researchers]*  
*This research is being conducted as part of an Honours degree in the School of Psychology, 
UTAS. 
 
We invite you to participate in a study aiming to understand how caffeine affects cognitive 
processes such as attention and associated brain activity. It is important to understand how 
caffeine affects attention and this may have implications for driver and worker safety. 
 
Why have I been invited to participate in this research? 
You are invited to take part in the study if you are aged 18-30 years old and if you typically 
consume a no more than 100mg of caffeine per day (approximately 1 single shot of coffee, or 1 
x energy drink, or 2 x cups of tea), and experience no adverse effects when you do consume 
caffeine. In order for the results of the study to be clear, all participants need to have normal 
or corrected to normal vison and hearing, speak English fluently, have no previous 
neurological, serious physical, or mental health problems, or current use of psychoactive 
medications. In addition, participants must NOT regularly use illicit drugs, smoke cigarettes 
daily, or consume alcohol at harmful levels. Female participants must not currently be 
pregnant or breast-feeding 
 
What will my participation involve? 
Participation is unlikely to cause any discomfort or distress. Firstly, if you are interested in 
taking part in the study, you will be invited to complete a confidential screening questionnaires 
including some basic information about yourself (such as age, sex, years of schooling) and to 
ensure that you are not taking medications or experiencing other issues that may affect brain 
activity. This will include a psychological distress scale, and some questions regarding your 
alcohol and drug use. All data collected will be kept in the strictest confidence as described 
below.  
 
Participation will involve two 2-hour sessions at the Cognitive Neuroscience Lab at the 
University of Tasmania in Hobart. During each testing session, you will be fitted with an 
electrode cap for measuring your brain activity. You will then be asked to complete some 
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computer-based tasks which relate to cognitive processes such as attention. In these tasks you 
will respond with a button press when particular objects appear on the screen. Before 
completing the tasks for a second time, you will be asked to ingest a capsule which may 
contain either caffeine or placebo. The caffeine doses used in this study have been considered 
safe by a panel of experts and are unlikely to cause any adverse effects. First year psychology 
students will receive up to 4 hours course credit. Other participants will receive a $30 gift 
voucher for reimbursement of time and out-of-pocket expenses. 
 
In the unlikely event that you do experience unpleasant side effects while completing the 
testing, a first aid officer will be available on site to provide further assistance if required. 
Additionally, the researcher will explain that in the unlikely event of you experiencing an 
adverse reaction once you have left the premises, you should contact your doctor or be taken 
to hospital immediately. 
 
There are no specific risks associated with the measurement of brain activity. However, if you 
have sensitive skin there is a small possibility of a slight skin reaction from electrode 
preparation materials. If you believe there is a chance that your skin may react, you are 
advised to reconsider participation. 
 
How private is the information that I give? 
All data collected will be kept in the strictest confidence. All data will be identified by a coding 
system and no names or contact numbers will appear on any records. In this way, your identity 
is protected, and there will be no risk of legal or social problems arising from your participation 
in the study. Your contact information will be kept in a separate password protected file with 
your ID code, and this file will only be accessible to the researchers. 
 
All information gathered in the study will be reported as grouped data, and because no 
personal information is recorded, no individual participants will be identifiable. Data from the 
study will be stored securely for fifteen years in locked cabinets or secure computer servers at 
the University of Tasmania, as is legally required, and then securely destroyed. 
 
Can I withdraw from the research if I wish? 
Participation in this study is entirely voluntary. You may, at any time, decline to answer any 
question you so wish, or withdraw from the study without effect or explanation.  
 
You will be given a copy of this information sheet to keep. Please keep this in case you decide 
at a later date that you would like to retract your data from the study. If you wish to withdraw 
your data, you may request this prior to the 31st of August, 2018, after which time the results 
will be published and your contact information will be destroyed. 
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Who do I need to contact if I have any questions about the research? 
If you would like more information about the research, please contact Dr Allison Matthews on 
62267236 (or email Allison.Matthews@utas.edu.au). If you would like to find out about the 
results of the study, these will be available from Dr Matthews after January 2019 or at the Utas 
Cog Neuro Lab facebook page 
 
Has this research been approved by an ethics committee? 
This project has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. If you have any concerns of an ethical nature, or complaints about 
the manner in which the study is conducted, you may contact the Executive Officer of 
the Human Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or 
human.ethics@utas.edu.au. Please quote the ethics reference number H11386. 
Who can I contact if I have any concerns? 
If you have any personal concerns related to the study, you may choose to discuss these 
concerns confidentially with a counsellor at the University Psychology Clinic free of charge. 
Confidential appointments may be made on (03) 6226 6254. 
 
Thank you for your interest in the study and for taking the time to read this information sheet. 
We hope you will be interested in participating in this study. 
 
Allison Matthews & Raimondo Bruno  XXX / XXX 
Chief Investigators                      Student Researchers   
(03) 6226 7236 or (03) 6226 2190  
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CONSENT FORM 
 
The Effect of Caffeine on Attentional Networks 
  
1. I have read and understood the 'Information Sheet' for this study. 
2.  I understand that the dose of caffeine used in the study is not expected to give rise to 
any serious safety concerns  
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves: 
• Attending two testing sessions of approximately two hours duration 
• Consuming a capsule which may contain caffeine 
• Completing a series of questionnaire and computer tasks while my brain activity 
is measured 
5. I understand that all research data will be securely stored on the University of Tasmania 
premises for five years, and will then be destroyed. 
6. Any questions that I have asked have been answered to my satisfaction. 
7. I agree that research data gathered from me for the study may be published provided 
that I cannot be identified as a participant. 
8. I understand that the researchers will maintain my identity confidential and that any 
information I supply to the researcher(s) will be used only for the purposes of the 
research. 
9. I agree to participate in this investigation and understand that I may withdraw any 
time without any effect. I may also request to withdraw my data from the research 
prior to the 31st August, 2018. 
 
 
Name of Participant: 
Signature: Date: 
 
Statement by Investigator  
 I have explained the project & the implications of participation in it to this 
volunteer and I believe that the consent is informed and that he/she 
understands the implications of participation  
 
Name of Investigator: 
Signature: Date: 
 
